CD36-Binding Aptamers for Targeted Drug Delivery
This technology offers CD36-binding aptamers with various potential applications, including the isolation or depletion of monocytes or macrophages, targeting platelets, and delivering drugs specifically to sites of inflammation or injury.
CD62L (L-Selectin) Aptamer for T Cell Isolation
A novel aptamer technology designed to isolate naïve and memory T cells by targeting the CD62L (L-Selectin) marker, facilitating applications in diagnostics, therapeutics, and research. The aptamer can also be used to detect soluble CD62L, a potential diagnostic marker for various diseases.
Constitutively Active cGAS for Enhanced Immune Response
This technology involves the design of constitutively active cyclic GMP-AMP synthase (cGAS) mutants that stimulate a robust immune response without the need for DNA binding.
Custom Transmembrane β-Barrel Proteins
This technology involves the design of eight-stranded transmembrane β-barrel proteins (TMBs) with no homology to known TMBs, offering potential for a wide range of synthetic biology applications.
Deep Learning Approaches for Protein Scaffolding
This technology uses advanced deep learning methods to design proteins with specific functional sites, offering a novel approach to protein design that is both efficient and versatile.
Homo-Oligomeric Protein Assemblies
The solution is a novel approach to design polypeptides that form cyclic homo-oligomers, offering potential applications in various fields.
Integrin α4β1-Specific DNA Aptamer Conjugates
A novel DNA aptamer-polymer conjugate designed to selectively bind integrin α4β1 (VLA-4), offering potential treatments for T-cell based autoimmune disorders and T-cell malignancies.
MEK Inhibition for Treating Darier Disease and Skin Fragility Disorders
A novel therapeutic approach utilizing MEK inhibitors to treat Darier disease and other skin fragility disorders by targeting the underlying molecular pathways.
Minibinder-Drug Conjugates Targeting Human EpCAM and PDL1 Receptors for Targeted Cancer Therapy
This technology offers a set of novel polypeptides designed to bind to human EpCAM and PDL1 receptors, offering potential applications in treating cancer, autoimmune diseases, and inflammation.
Mixed Chirality Peptide Macrocycles with Internal Symmetry
This technology leverages computational design to create mixed chirality peptide macrocycles with internal symmetry, offering a new avenue for therapeutic and nanomaterial design.
Modulating Prime Editing Efficiency Through Epigenetic Reprogramming
The innovation is a method that involves reprogramming the epigenetic environment in the vicinity of a target site to modulate prime editing efficiency.
Nanoactuators Based FePd Nanohelices to Initiate Cell Apoptosis
This technology offers a nano-actuator to initiate apoptosis and the removal of cancer cells. The nano-actuators are magnetically propelled to target cells and then oscillate, causing mechanical damage to the cells.
Novel Nanoparticle Immunogens for Influenza Vaccines
This technology offers a new approach to influenza vaccines using computationally designed nanoparticle immunogens that elicit potent, neutralizing antibodies against influenza viruses.
Protective Monoclonal Antibodies for Reducing Pseudomonas aeruginosa Burden
High-affinity monoclonal antibodies derived from cystic fibrosis patients' B cells show potent activity against Pseudomonas aeruginosa, offering a promising treatment for vulnerable patients.
Protein Homodimers with Tunable Symmetric Pockets: A Novel Approach to Binding Symmetric Molecules
This technology offers de novo designed protein homodimers with tunable symmetric pockets, enabling the binding of symmetric molecules for diverse applications.
Systems and Methods for Deep Brain Stimulation Using Kinematic Feedback for Treatment of Movement Disorders
This technology offers the statistical analysis of gait parameters, a motor symptom of Parkinson’s disease. This system conducts deep brain stimulation and adapts its response with the stimulation frequency varying between low (i.e. 60 Hz) and high (>130 Hz) frequencies to improve gait.
Targeted Protein Degradation in Bacteria Contributes to Antibiotic Efficacy
The solution is a method to develop new antibiotic proteolysis targeting chimeras (PROTACs) that target proteins of interest for degradation in bacteria to counteract antibiotic resistance.
Transferrin Receptor-Binding Aptamers for Cancer Cell Depletion in Adoptive T-Cell Therapy
Innovative DNA aptamers that bind to the transferrin receptor (TfR1) offer a novel method for depleting cancer cells from therapeutic cell populations, enhancing the safety and efficacy of adoptive T-cell therapies. Additionally, these aptamers may be used for targeted delivery via the transferrin receptor.